No Data
Biotechnology Market: Surging Investments and Infrastructure Development Propel 13.9% CAGR by 2031| SkyQuest Technology
Insiders At Adaptive Biotechnologies Sold US$664k In Stock, Alluding To Potential Weakness
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
Express News | Adaptive Biotechnologies Says Its Next-generation Sequencing-based ClonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment With ClonoSEQ To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress